Search

Iovance Biotherapeutics Inc

Geschlossen

BrancheGesundheitswesen

8.61 0.47

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

8.25

Max

8.68

Schlüsselkennzahlen

By Trading Economics

Einkommen

32M

-47M

Verkäufe

28M

99M

EPS

-0.11

Gewinnspanne

-47.642

Angestellte

975

EBITDA

32M

-39M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+10.39% upside

Dividenden

By Acuity

Nächstes Ergebnis

5. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.8B

3.7B

Vorheriger Eröffnungskurs

8.14

Vorheriger Schlusskurs

8.61

Nachrichtenstimmung

By Acuity

38%

62%

101 / 340 Ranking in Healthcare

Iovance Biotherapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Sept. 2026, 19:16 UTC

Iovance Biotherapeutics is up today, continuing a trend of three consecutive higher daily closes despite rising global bond yields and no specific news.

1. Sept. 2026, 23:06 UTC

Iovance Biotherapeutics Inc shares are lower in after-market hours, reflecting a slight decline since Tuesday's close amid rising oil prices and inflation concerns.

31. Aug. 2026, 19:36 UTC

News

Iovance Biotherapeutics shares are lower amid increased interest rate hike expectations and uncertainties regarding its product execution and approvals.

28. Aug. 2026, 23:11 UTC

Iovance Biotherapeutics Inc is trading higher in after-market hours, remaining near the upper end of its one-month range and above its 20-day moving average.

27. Aug. 2026, 23:01 UTC

Iovance Biotherapeutics Inc shares are lower in after-market hours amid a broader market decline influenced by recent economic data and Fed policy expectations.

26. Aug. 2026, 23:46 UTC

Iovance Biotherapeutics is trading higher in after-market hours, showing unusual activity and remaining above its 20-day moving average. No specific news was identified.

25. Aug. 2026, 19:16 UTC

News
Social Media

TD Cowen maintained a Buy rating on Iovance Biotherapeutics and raised its price target to $10, contributing to the stock's gains since Monday.

24. Aug. 2026, 23:26 UTC

Iovance Biotherapeutics shares are higher in after-market trading, continuing an upward trajectory since Monday's close, despite recent declines over three sessions.

21. Aug. 2026, 20:02 UTC

Iovance Biotherapeutics is lower in Friday's session, with no specific news identified. The broader market also remains down significantly since Thursday's close.

20. Aug. 2026, 23:06 UTC

News

Iovance Biotherapeutics reached a 52-week high after UBS raised its target price to $7, noting strong second-quarter sales of $91 million.

19. Aug. 2026, 23:16 UTC

News
Social Media

Iovance Biotherapeutics shares reached a new 52-week high amid positive melanoma treatment sector sentiment and an anticipated revenue guidance increase.

18. Aug. 2026, 23:06 UTC

Iovance Biotherapeutics shares were roughly flat in after-market hours. The broader market faced pressure from rising bond yields and increased oil prices.

17. Aug. 2026, 19:36 UTC

Social Media

Iovance Biotherapeutics reaches a new 52-week high above $7 amid positive results from the IOV-LUN-202 trial for metastatic NSCLC.

14. Aug. 2026, 23:26 UTC

Social Media

Iovance Biotherapeutics Inc. gains in after-market trading, reaching a 52-week high above $7 amid positive sentiment for IOV-LUN-202 and upcoming updates.

13. Aug. 2026, 19:21 UTC

Iovance Biotherapeutics Inc shares are lower today, reaching a midday low after earlier gains. No specific news was identified to explain the decline.

12. Aug. 2026, 19:16 UTC

Social Media

Iovance Biotherapeutics Inc shares rise amid positive social media discussions and analyst projections of over $400 million in revenue this year.

11. Aug. 2026, 23:46 UTC

Iovance Biotherapeutics Inc shares are lower in after-market hours amid volatility. No specific news was identified to explain the price movement.

10. Aug. 2026, 23:56 UTC

News

Iovance Biotherapeutics reported second-quarter revenue of $99.3 million, a 66% increase, contributing to a rise in shares during after-market hours.

7. Aug. 2026, 20:03 UTC

News
Social Media

Iovance Biotherapeutics rises as Barclays and Citizens raise price targets amid positive sentiment and high trading volume.

6. Aug. 2026, 20:03 UTC

Social Media
News

Iovance Biotherapeutics reported record Q2 revenue of $99.3 million, exceeding estimates. The stock is higher amid strong demand and FDA Fast Track Designation for SAR-201.

5. Aug. 2026, 23:16 UTC

Iovance Biotherapeutics shares are higher in after-market trading, reflecting broader market strength amid falling crude oil prices and strong corporate earnings.

4. Aug. 2026, 19:51 UTC

Iovance Biotherapeutics is rising amid broader market strength from falling crude oil prices and positive economic data, despite lingering inflation concerns.

3. Aug. 2026, 19:51 UTC

Iovance Biotherapeutics shares are higher today, rebounding from an earlier low. The stock has advanced since Friday, amid positive market sentiment.

31. Juli 2026, 23:41 UTC

Iovance Biotherapeutics shares are higher in after-market trading, maintaining gains since Friday's close amid broader market volatility following a decline in Apple shares.

30. Juli 2026, 23:51 UTC

Iovance Biotherapeutics shares are lower in after-market trading, reflecting ongoing weakness and pulling back from a brief session high earlier.

29. Juli 2026, 15:16 UTC

Iovance Biotherapeutics Inc shares are lower today, continuing a trend of declines over the past six sessions with no specific news identified.

28. Juli 2026, 23:56 UTC

Iovance Biotherapeutics shares declined in after-market trading, continuing a trend of lower finishes over the past five sessions. No specific news was identified.

27. Juli 2026, 19:36 UTC

Social Media

Iovance Biotherapeutics is lower today, continuing a trend of declines over four consecutive trading days. Earlier, shares rebounded from a session low.

24. Juli 2026, 19:12 UTC

Iovance Biotherapeutics Inc shares are lower today, continuing a downward trend amid broader market volatility influenced by falling oil prices and geopolitical tensions.

22. Juli 2026, 23:11 UTC

Iovance Biotherapeutics shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector. The stock remains near its one-month trading range high.

Peer-Vergleich

Kursveränderung

Iovance Biotherapeutics Inc Prognose

Kursziel

By TipRanks

10.39% Vorteil

12-Monats-Prognose

Durchschnitt 9.14 USD  10.39%

Hoch 13 USD

Tief 6 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Iovance Biotherapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

5

Buy

2

Halten

0

Sell

Stimmung

By Acuity

101 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
help-icon Live chat